Overview
Patricia Bougie-Gomez practices practicing medicine in Nantes, France.
Ms. Bougie-Gomez is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Multiple Myeloma and Mantle Cell Lymphoma (MCL).
She is actively involved in clinical research, co-authoring 26 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Patricia Bougie-Gomez
Is Patricia Bougie-Gomez a top-rated expert for Multiple Myeloma?
MediFind is an objective health platform that identifies experts based on real-world data. Patricia Bougie-Gomez is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Patricia Bougie-Gomez participate in research or clinical trials?
Yes. Patricia Bougie-Gomez has published 26 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Patricia Bougie-Gomez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Multiple MyelomaMs. Bougie-Gomez isAdvanced. Learn about Multiple Myeloma.
- Experienced
- Mantle Cell Lymphoma (MCL)Ms. Bougie-Gomez isExperienced. Learn about Mantle Cell Lymphoma (MCL).